Botulinum toxin type A in primary axillary hyperhidrosis: A 52 week, multicenter, double-blind, randomized, placebo-controlled trial

被引：1
|
作者：
Lowe, NJ
Glaser, DA
机构：
[1] Univ Calif Los Angeles, Los Angeles Dept Dermatol, Santa Monica, CA USA
[2] St Louis Univ, Med Ctr, St Louis, MO USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2004年 / 50卷 / 03期
关键词：
D O I：
10.1016/j.jaad.2003.10.199
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P195
引用
收藏
页码：P50 / P50
页数：1
相关论文
共 50 条
  • [21] Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial
    Ryuji Kaji
    Yuka Osako
    Kazuaki Suyama
    Toshio Maeda
    Yasuyuki Uechi
    Masaru Iwasaki
    Journal of Neurology, 2010, 257 : 1330 - 1337
  • [22] Botulinum toxin type A in post-stroke lower limb spasticity: a multicenter, double-blind, placebo-controlled trial
    Kaji, Ryuji
    Osako, Yuka
    Suyama, Kazuaki
    Maeda, Toshio
    Uechi, Yasuyuki
    Iwasaki, Masaru
    JOURNAL OF NEUROLOGY, 2010, 257 (08) : 1330 - 1337
  • [23] Botulinum toxin type A in migraine without aura prophylaxis; a 12-week prospective, multicentre, double-blind, randomized, placebo-controlled trial
    Chankrachang, S
    Arayawichanont, A
    Poungvarin, N
    Nidhinandana, S
    Boonkongchuen, P
    Towanabut, S
    Sithinamsuwan, P
    Kongsaengdao, S
    CEPHALALGIA, 2005, 25 (10) : 992 - 993
  • [24] Treatment of Neuropsychiatric Symptoms in Parkinson's Disease With Botulinum Toxin A: A 12 week Randomized, Double-Blind, Placebo-Controlled Trial
    Zhu, Xiaofeng
    Wei, Ming
    Wang, Lijun
    Tong, Qiang
    Yang, Xiu
    Han, Qiu
    JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY, 2024,
  • [25] Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (Botulinum toxin type B) for the treatment of palmar hyperhidrosis
    Baumann, L
    Slezinger, A
    Halem, M
    Vujevich, J
    Mallin, K
    Charles, C
    Martin, LK
    Black, L
    Bryde, J
    DERMATOLOGIC SURGERY, 2005, 31 (03) : 263 - 270
  • [26] Hengli(R) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
    Liao, Limin
    Liu, Qinggang
    Cong, Huiling
    Xu, Zhihui
    Li, Enhui
    Weng, Zhiliang
    Jiang, Haihong
    Liu, Ben
    Huang, Xiao
    Xia, Shujie
    Wen, Wei
    Wu, Juan
    Shi, Guowei
    Wang, Yang
    Li, Peijun
    Yu, Yang
    Fang, Zujun
    Zheng, Jie
    Tian, Ye
    Shang, Donghao
    Li, Hanzhong
    Huang, Zhongming
    Zhou, Liqun
    Xiao, Yunxiang
    Zhang, Yaoguang
    Wang, Jianlong
    Zhang, Xiaodong
    Zhang, Peng
    Wang, Dongwen
    Zhang, Xuhui
    Xie, Keji
    Wang, Bin
    Ma, Lulin
    Tian, Xiaojun
    Chen, Lijun
    Dong, Jinkai
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [27] Botulinum toxin type A (BOTOX®) for the prophylactic treatment of chronic daily headache:: A randomized, double-blind, placebo-controlled trial
    Mathew, NT
    Frishberg, BM
    Gawel, M
    Dimitrova, R
    Gibson, J
    Turkel, C
    HEADACHE, 2005, 45 (04): : 293 - 307
  • [28] Botulinum toxin type A for the prophylaxis of chronic daily headache (CDH) in migraineurs: A randomized, double-blind, placebo-controlled trial
    Frishberg, BM
    Mathew, NT
    Gawel, M
    DeGryse, R
    Turkel, C
    HEADACHE, 2005, 45 (06): : 773 - 774
  • [29] Pentoxifylline in ALS: A double-blind, randomized, multicenter, placebo-controlled trial
    Levin, B
    Thompson, JLP
    Levy, G
    Mitsumoto, H
    Kaufmann, P
    NEUROLOGY, 2006, 66 (11) : 1786 - 1786
  • [30] Pentoxifylline in ALS - A double-blind, randomized, multicenter, placebo-controlled trial
    Meininger, V
    Asselain, B
    Guillet, P
    Leigh, PN
    Ludolph, A
    Lacomblez, L
    Robberecht, W
    NEUROLOGY, 2006, 66 (01) : 88 - 92
12345